MEETING, Pa., June 27,
2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a
biotechnology company focused on developing and commercializing DNA
medicines to help protect people from infectious diseases and treat
people with cancer and HPV-associated diseases, today announced the
appointment of Dr. Michael Sumner, MB BS, MBA, as Chief Medical
Officer (CMO). Dr. Sumner will oversee INOVIO's clinical-stage
pipeline of DNA medicines, global clinical development, clinical
operations and biostatistics efforts, as well as regulatory
affairs, pharmacovigilance and medical affairs. He will serve on
the company's executive leadership team and will report to INOVIO's
President and Chief Executive Officer, Dr. Jacqueline Shea.
INOVIO's President and Chief Executive Officer, Jacqueline Shea, Ph.D., said, "INOVIO is pleased
to welcome Dr. Sumner to INOVIO. An industry veteran and a member
of the Royal College of Physicians, Dr. Sumner's clinical
development and medical affairs expertise and track record of
helping guide companies through regulatory approval and
commercialization make him an important addition to the INOVIO
Dr. Sumner joins INOVIO after serving as CMO of Orexo AB since
2013. He previously held numerous European- and US-based leadership
roles at Novartis Pharmaceuticals, Aventis
Behring, Novo Nordisk and Shire Pharmaceuticals. Dr. Sumner
brings over 25 years of extensive pharmaceutical, medical and
clinical experience driving numerous late-stage product approvals
and supporting successful commercial products on a global
basis across multiple therapeutic areas.
Dr. Sumner received his medical degree from the University
of London, is a member of the
Royal College of Physicians, and holds a Master of Business
Administration from Henley Management College, UK.
"I am pleased to join INOVIO as CMO and look forward to working
with the team to unlock the power of the DNA Medicines platform to
address unmet medical need," said Dr. Sumner.
INOVIO is a biotechnology company focused on developing and
commercializing DNA medicines to potentially treat and protect
people from infectious diseases, cancer, and diseases associated
with HPV. INOVIO's DNA medicines are delivered using its
proprietary smart device to produce a robust and tolerable immune
response against targeted pathogens and cancers.
For more information, visit www.inovio.com.
Matone, 484-362-0076, email@example.com
Media: Jeff Richardson,
SOURCE INOVIO Pharmaceuticals, Inc.